Hans Aerni

Executive Director, CMC Analytical Development at Janux Therapeutics

Hans Aerni has over 20 years of work experience in the field of chemistry. Hans began their career in 1991 as a Chemistry Intern at The Swiss NBC Defense Establishment, where they acquired a variety of skills such as NMR spectroscopy, atomic absorption spectroscopy, metal analysis, and more. In 1999, they moved on to become a Research Scientist at EAWAG, where they developed an ultra-sensitive method for the analysis of steroids in wastewater and surface water. From 2002 to 2011, they worked at Vanderbilt University, first as a Graduate Student and then as a Research Assistant, where they developed sample coating technologies for MALDI Imaging MS and analyzed clinical tissue specimens. From 2011 to 2016, they were a Postdoc at Yale University, where they used quantitative mass spectrometry to characterize a genomically engineered organism and newly developed orthogonal translation systems for site-specific incorporation of non-standard amino acids. From 2016 to 2021, they were a Scientist I, Scientist II, and Principal Scientist at Synthorx Inc. Hans is currently employed as the Senior Director of CMC Analytical Development at Janux Therapeutics.

Hans Aerni obtained a Doctor of Philosophy (PhD) from Vanderbilt University in 2011, with a focus on bioanalytical mass spectrometry and protein marker discovery in clinical tissue specimen. Prior to this, they earned a Bachelor's Degree in Analytical Chemistry from HTA-BE Hochschule für Technik und Architektur Bern in 1999.

Location

San Diego, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Janux Therapeutics

1 followers

Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.


Industries

Employees

51-200

Links